Therapeutically, targeting NMDA receptors, modulating catabolic pathways for efficient debris clearance, and mitigating OS through interventions in NAD(P)H oxidase activity represent potential strategies for managing MS-related neurodegeneration and inflammation. The gene discussed is FMO5; the disease is myeloid sarcoma.